| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
1990-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e48dac932505109472e62e4538d64909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6a2716a08e830f232ae87fdd2e6a11f |
| publicationDate |
2000-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-218146-B |
| titleOfInvention |
Improved meningococcal polysaccharide conjugate vaccine |
| abstract |
By replacing the N-acetyl groups of the sialic acid residues with N-acyl groups, the modified Neisseria meningitidis Group B polysaccharide (GBMP) induces an enhanced immune response. In addition, a minimal amount of antibody is formed that is unmodified group B. meningitidis and E. coli K1 cross-reacts with the co-polysaccharide and other tissue cells with the same epitope. Modified polysaccharides conjugated to a physiologically acceptable protein, such as tetanus toxoid, induce the production of specific protective antibodies with negligible amounts of human and animal neural cell adhesion antigens, thereby providing effective protection against group B meningococci and E. coli K1 infections. ŕ |
| priorityDate |
1989-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |